Add time:08/11/2019 Source:sciencedirect.com
BackgroundWe previously reported that alendronate and risedronate reduce the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) by 44.9% and 34.7%, respectively, at 3 months after the start of treatment, and increase the speed of sound (SOS) of the calcaneus by 0.6% and 0.65%, respectively, at 12 months after the start of treatment in postmenopausal women with osteoporosis. The aim of the present clinical practice-based observational study was to examine the effect of treatment with MINODRONATE (cas 127657-42-5) for 12 months on the SOS of the calcaneus and on bone turnover markers in postmenopausal women with an increased risk of fractures.
We also recommend Trading Suppliers and Manufacturers of MINODRONATE (cas 127657-42-5). Pls Click Website Link as below: cas 127657-42-5 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View